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INTRODUC TION
An increasing number of published reports on SARS- CoV- 2 neuro-
logical manifestations have revealed a wide spectrum of symptoms, 
diagnostic features, and outcomes [1,2]. We report a fatal case of a 
COVID- 19- associated acute necrotizing encephalopathy (ANE).
C A SE REPORT
On 13 January 2021, a stuporous 70- year- old man was brought to 
the emergency department (ED). An hour earlier, he complained of a 
severe headache, and his blood pressure was 237/129 mmHg, after 
which he collapsed and had a generalized tonic- clonic seizure. Upon 
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Introduction: An increasing number of published reports on SARS- CoV- 2 neurological 
manifestations have revealed a wide spectrum of symptoms, diagnostic features, and 
outcomes. We report a fatal case of a COVID- 19- associated acute necrotizing encepha-
lopathy (ANE).
Case report: We report a 70- year- old man brought to the hospital after a generalized 
tonic- clonic seizure. He was confused and disoriented. Nasopharyngeal swab testing for 
SARS- CoV- 2 was positive. A head computed tomography (CT) scan and cerebrospinal 
fluid (CSF) analysis showed no signs of acute pathology. After recurrent seizures, he was 
sedated and intubated. Throughout the days that followed he remained in a therapeutic 
coma. After discontinuation of sedatives, he remained unconscious. A repeated head CT 
scan showed signs of pontine edema, and brain magnetic resonance imaging (MRI) re-
vealed inhomogeneous hyperintensities with microhemorrhages and small autonecrotic 
cavities in both thalami, brain stem, and cerebellar peduncles. With a high suspicion of a 
COVID- 19- associated ANE, the patient was started on high- dose glucocorticoids; how-
ever, he died the next day. The CSF tested negative for SARS- CoV- 2.
Discussion: A variety of COVID- 19 neurological manifestations have been reported to 
date, including various forms of encephalitis and encephalopathy. In our patient, enceph-
alopathy with seizures was the presenting symptom of SARS- CoV- 2 infection. The radio-
logical findings on days 8 and 9 were consistent with an ANE. The precise pathogenesis of 
ANE remains unclear; however, an immune- mediated mechanism is suspected. Early di-
agnostics with prompt administration of immunomodulators may be lifesaving. Suspicion 
of a COVID- 19- related encephalopathy/encephalitis should be raised in all patients with 
altered mental status, seizures, and/or coma.
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arrival at the ED, he was confused and disoriented, without other 
obvious signs of focal neurological damage. The patient's medical re-
cords showed a history of poorly treated hypertension, heart failure, 
diabetes, and obesity, as well as a previous intracerebral hemorrhage 
(2017) and an ischemic left middle cerebral artery stroke (2018). A 
history of frequent alcohol consumption was also noted. A head 
computed tomography (CT) scan, CT angiography (Figure 1a), blood 
tests, and a lumbar puncture were performed, revealing no acute pa-
thology or signs of acute inflammation. Nasopharyngeal swab testing 
for SARS- CoV- 2 was positive and his chest CT scan demonstrated 
signs of bilateral pneumonia. After recurrent convulsive seizures, 
the patient was sedated, intubated, and hospitalized in the intensive 
care unit (ICU). The patient remained in a therapeutic coma through-
out the days that followed, and had a continuous fever of up to 39°C. 
Blood tests showed elevated acute phase proteins (interleukin- 6 [IL- 
6] 51.3 pg/mL, C- reactive protein [CRP] 243.85 mg/L, and lactate 
dehydrogenase [LDH] 245.83 U/L), progressive pancytopenia, and 
a significant hyperferritinemia. Ferritin and LDH levels had a subse-
quent upward trend. After discontinuation of sedatives, the patient 
did not regain consciousness, and a repeat neurology consultation 
was required. On 20 January, he became bradycardic and hypoten-
sive. His neurological status was consistent with a coma (Glasgow 
Coma Scale score of 3). A repeated head CT scan (Figure 1b) showed 
signs of edematous changes in the pons. An urgent brain magnetic 
resonance imaging (MRI) scan revealed edematous changes in both 
thalami, brain stem, and cerebellar peduncles (Figure 1c) with micro-
hemorrhages (Figure 1e), small autonecrotic cavities, and restricted 
diffusion (Figure 1f). Also, some patchy contrast enhancement was 
observed in the brain stem (Figure 1d). With a high suspicion of a 
COVID- 19- associated ANE, the patient was started on high- dose 
glucocorticoids; however, his overall status deteriorated, and he 
died the next day. The previously obtained cerebrospinal fluid (CSF) 
specimen was tested for SARS- CoV- 2, but no viral RNA was found.
DISCUSSION
The number of reports on SARS- CoV- 2 extrapulmonary manifesta-
tions continues to grow, revealing a significant number of patients 
presenting with neurological symptoms. Central nervous system 
(CNS) involvement has been described in COVID- 19- associated 
encephalopathy, acute disseminated encephalomyelitis, limbic en-
cephalitis, myelitis, ANE, and stroke [2]. ANE is a rare type of rapidly 
progressing encephalopathy, with altered consciousness, seizures, 
and focal neurological deficits. Radiologically, it is characterized by 
multiple bilaterally distributed lesions within the thalamus, basal 
ganglia, brainstem, and subcortical white matter [3,4]. ANE has been 
previously linked to various infectious pathogens, including influ-
enza A and B, herpes simplex virus, and others. Our case adds to 
the few reports of ANE associated with SARS- CoV- 2 infection (Table 
S1).
Our patient presented with altered mental status and recurrent 
seizures, without other focal neurological deficits. To the best of 
our knowledge, no respiratory symptoms were observed before the 
onset of neurological symptoms, suggesting that encephalopathy 
with seizures was the presenting symptom of SARS- CoV- 2 infection.
Due to a suspected status epilepticus, the patient was sedated 
and kept in a therapeutic coma; however, the unavailability of elec-
troencephalography for COVID- 19- positive patients in our hospital 
limits the drawing of further conclusions. The head CT scan on ad-
mission showed no signs of cerebral damage; however, the head CT 
and MRI on days 8 and 9, accordingly, demonstrated prominent CNS 
involvement, highlighting a rapid progression of the disease. The ra-
diological findings were consistent with ANE.
The precise pathogenesis of ANE remains unclear. However, 
an immune- mediated mechanism involving pro- inflammatory cyto-
kines, rather than a direct invasion of a pathogen, is suspected [3]. In 
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our case, such a mechanism can be supported by the elevated IL- 6, 
CRP, LDH, and ferritin found in the patient's serum. Reports of dra-
matic patient improvement after glucocorticoid or plasma exchange 
therapy support the theory of an immune- mediated mechanism [5]. 
The CSF sample being negative for SARS- CoV- 2 also contradicts the 
hypothesis of a direct CNS invasion. Unfortunately, the patient's 
CSF was not tested for other possible etiological factors, including 
autoimmune antibodies, and the patient's family refused an autopsy, 
thus limiting further conclusions.
Although it has been proven to be a challenge, early diagnosis 
with prompt administration of immunomodulatory therapy may be 
lifesaving [5]. The clinical suspicion of a COVID- 19- related encepha-
lopathy/encephalitis should be raised in all patients with COVID- 19, 
altered mental status, seizures, and/or coma.
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